Rocket Pharmaceuticals in-27RCKTWPreferred / convertible
13F holders, Q3 2024 (September 30)14holders
2new positions
2sold out
1famous investor
$0.28avg. 13F price*
At the end of Q3 2024, 14 institutions reported holding Rocket Pharmaceuticals in-27 (RCKTW) in their 13F filings, unchanged from Q2 2024. 2 opened new positions and 2 sold out. The largest holders were Boothbay Fund Management, LLC ($682K), Altium Capital Management LLC ($51K) and Walleye Capital LLC ($50K). One famous investor held it Ken Griffin ( of Citadel Advisors's portfolio).
- Company
- Rocket Pharmaceuticals in-27
- CUSIP
- 77313F114
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q2 2024 → Q3 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 2 | $13 |
| Exits | 2 | $4K |
All 13F filers, Q2 2024 → Q3 2024: 200 shares bought and 167,414 shares sold, net −167,214 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 14 holders
| Boothbay Fund Management, LLC | — | No change | 36,912 | $682K |
| Altium Capital Management LLC | — | No change | 731,561 | $51K |
| Walleye Capital LLC | — | No change | 720,905 | $50K |
| Sio Capital Management, LLC | — | No change | 400,000 | $29K |
| Citadel Advisors | — | Reduce -7.3% | 343,397 | $24K |
| Fort Baker Capital Management LP | — | No change | 328,698 | $24K |
| RTW Investments, LP | — | No change | 350,000 | $23K |
| Silverarc Capital Management, LLC | — | No change | 104,828 | $7K |
| Susquehanna International Group, LLP | — | Reduce -46.6% | 90,947 | $6K |
| Affinity Asset Advisors, LLC | — | No change | 75,000 | $5K |
| Walleye Trading LLC | — | No change | 34,829 | $2K |
| Ancora Advisors LLC | — | No change | 6,000 | $433 |
| Clear Street LLC | — | New | 100 | $7 |
| Bank of America Corp. | — | New | 100 | $6 |
"% of holder's portfolio" is RCKTW's weight in each manager's 13F, not the share of Rocket Pharmaceuticals in-27 the manager owns.